Stentless vs. stented bioprosthesis for aortic valve replacement: A case matched comparison of long-term follow-up and subgroup analysis of patients with native valve endocarditis - Fig 1

<p><b>Kaplan-Meier survival curve for survival comparison of Sorin Freedom Solo and Carpentier Edwards Perimount bioprosthetic heart valves (A) and survival probability for patients with or without re-do surgery after index procedure [no = without re-do surgery; yes = with re-do surgery] (B)</b>.</p

Clinical 30-day outcome and echocardiographic results at discharge.

<p>Clinical 30-day outcome and echocardiographic results at discharge.</p

Baseline demographics and matching results.

<p>Baseline demographics and matching results.</p

Forest-plot of multivariate COX-analysis with inclusion of four parameters; NVE native valve endocarditis.

<p>Forest-plot of multivariate COX-analysis with inclusion of four parameters; NVE native valve endocarditis.</p

Periprocedural data.

<p>Periprocedural data.</p

Baseline characteristics of 80 patients with Marfan syndrome and <i>FBN1</i> mutation.

<p>± standard deviation or numbers (percentage). Mean </p

According to the revised Ghent nosology [17] we identified disease causality for 80 <i>FBN1</i> mutations, as missense mutations affecting/creating cysteine residues in 25 (30%), nonsense mutations in 15 (19%), inframe and out of frame deletion/insertions in 14 (18%), missense mutations affecting conserved residues of the EGF consensus sequence in 9 (11%), other missense mutations in 9 (11%), splice site mutations in 6 (8%), and missense mutations creating cysteine residues in a EGF consensus sequence in 2 (3%) [17].

<p>According to the revised Ghent nosology <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0081281#pone.0081281-Loeys1" target="_blank">[17]</a> we identified disease causality for 80 <i>FBN1</i> mutations, as missense mutations affecting/creating cysteine residues in 25 (30%), nonsense mutations in 15 (19%), inframe and out of frame deletion/insertions in 14 (18%), missense mutations affecting conserved residues of the EGF consensus sequence in 9 (11%), other missense mutations in 9 (11%), splice site mutations in 6 (8%), and missense mutations creating cysteine residues in a EGF consensus sequence in 2 (3%) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0081281#pone.0081281-Loeys1" target="_blank">[17]</a>.</p

Ventricular arrhythmia in 80 patients.

<p> Five patients had >1 ventricular event.</p

Baseline characteristics according to arrhythmia.

<p> ACE-I identifies angiotensin converting enzyme inhibitors; ARB, angiotensin-receptor blockers; HDL cholesterol, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol, and nsVT, non-sustained ventricular tachycardia.</p><p>–Whitney test for continuous data and the Fisher's exact test for nominal and categorical data. Mann</p><p> Three patients received two or three different classes of drugs.</p

<i>FBN1</i> mutation characteristics according to arrhythmia.

<p>–Whitney test for continuous data and the Fisher's exact test for nominal and categorical data. Mann</p